1. Home
  2. GH vs VTRS Comparison

GH vs VTRS Comparison

Compare GH & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$161.97

Market Cap

20.6B

Sector

Health Care

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$17.59

Market Cap

18.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
VTRS
Founded
2011
1961
Country
United States
United States
Employees
N/A
30000
Industry
Medical Specialities
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.6B
18.7B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
GH
VTRS
Price
$161.97
$17.59
Analyst Decision
Strong Buy
Buy
Analyst Count
19
4
Target Price
$119.79
$13.50
AVG Volume (30 Days)
2.1M
8.5M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
3.21%
EPS Growth
6.74
N/A
EPS
N/A
0.15
Revenue
$982,021,000.00
$14,299,900,000.00
Revenue This Year
$33.30
$4.41
Revenue Next Year
$28.27
$1.96
P/E Ratio
N/A
$118.17
Revenue Growth
32.88
N/A
52 Week Low
$41.19
$8.74
52 Week High
$174.08
$18.07

Technical Indicators

Market Signals
Indicator
GH
VTRS
Relative Strength Index (RSI) 60.80 58.29
Support Level $152.64 $15.82
Resistance Level $174.08 N/A
Average True Range (ATR) 7.80 0.48
MACD -1.27 0.04
Stochastic Oscillator 54.90 71.54

Price Performance

Historical Comparison
GH
VTRS

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: